📑 CagriSema underperforms in latest trials
The latest data on CagriSema from REDEFINE-2 misses the mark set by REDEFINE-1
We’ve covered the combination of Semaglutide and Cagrilinitide (“CagriSema”) in the past, the results from the REDEFINE-1 clinical trial:
Unfortunately, the positive results of CagriSema were overshadowed by other factors affecting Novo Nordisk.
This time, there’s REDEFINE-2’s results are out, and while they’re objectively good for weight loss they fall short of the results of REDEFINE-1: